IRWD reported first-quarter 2023 adjusted earnings of 25 cents per share, which beat both the Zacks Consensus Estimate and our model estimates of 24 cents and 23.

.

By Rowan Walrath 鈥 Life Sciences Reporter, Boston Business Journal. .

.

.

80. Ironwood Pharmaceuticals Inc. Dec 1, 2021 7:51AM EST.

2 days ago 路 Tom McCourt is the CEO of Ironwood Pharmaceuticals.

Ironwood CEO Tom McCourt described his company's asset-to-be as "an ideal strategic fit" with its business. 15 billion, adding a promising treatment for digestive disorders to its portfolio. Ironwood鈥檚 Tom Graney tries to focus investors on the firm鈥檚 pipeline rather than its revenue.

. (鈥Ironwood鈥) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (鈥淰ectivBio鈥) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that they have entered into a definitive.

Ironwood Pharmaceuticals, Inc.

05 earnings per share for the current fiscal year.

Ironwood (Nasdaq: IRWD) is spending the. May 22, 2023.

Ironwood Pharmaceuticals is a patient-focused, biopharmaceutical company on a mission to push the boundaries of the gastrointestinal (GI) field by advancing the. 2 days ago 路 Ironwood Pharmaceuticals (IRWD 3.

.
The average price target represents.
May 22, 2023 路 BOSTON & BASEL, Switzerland--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc.

ET -.

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc.

1 day ago 路 As of May 11, 2023, the average one-year price target for Ironwood Pharmaceuticals Inc - is 13. . 00.

Research analysts expect that Ironwood Pharmaceuticals, Inc. . (formerly Sepracor Pharmaceuticals). . Meredith Kaya, 617-374-5082. Sr.

15 billion, adding a promising treatment for digestive disorders to its portfolio.

2 days ago 路 Ironwood Pharmaceuticals plans to buy a Swiss biotech for $1 billion as the Boston drug firm seeks to strengthen its focus on treatments for gastrointestinal diseases. .

A strong track record of commercial success--developed and led industry-leading.

.

.

.

Source: Ironwood Pharmaceuticals, Inc.